Deramciclane (EGIS-3886) is a drug which acts as an antagonist at the 5-HT2A receptor as an inverse agonist at the 5-HT2C receptor and as a GABA reuptake inhibitor.In 2003 Orion Pharma of Finland and partner Pharmacia discontinued the development of deramciclane for generalized anxiety disorder owing to a lack of efficacy in the combined results of the Phase III trials of the agent.
This page contains content from the copyrighted Wikipedia article "Deramciclane"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
